

21st Austria ATX-Prime Stocks Week 41

ATX TR			
3614.56	0.15%	5.23%	
Price	% week	% ytd	
Addiko Bank			
20.20	5.21%	51.31%	
Aluflexpack			
Agrana			
10.90	-0.46%	-22.70%	
Amag			
23.90	0.84%	-10.49%	
AT&S			
21.24	2.61%	-19.24%	
Bawag			
69.50	4.98%	44.85%	
stock3			
16.30	4.49%	-9.94%	
CA Immo			
25.98	-3.06%	-19.94%	
DO&CO			
149.00	2.19%	10.86%	
Erste Group			
49.58	2.06%	34.99%	
FACC			
6.33	-2.62%	8.58%	
Flughafen Wien			
52.60	3.14%	3.34%	
Frequentis			
25.70	-1.53%	-5.86%	
Immofinanz			
17.18	-4.24%	-18.38%	
Kapsch TrafficCom			
7.90	-1.00%	-11.83%	
Montana Aerospace			
Marinomed Biotech			
9.48	0.21%	-67.53%	
Palfinger			
21.00	-3.89%	-16.67%	
Pierer Mobility			
23.70	-1.25%	-52.31%	
Porr			

Dear active investors,

A quiet week for ATX TR, which went up 0,15 percent, we saw the lowest turnover in 2024. News came from wienerberger, Marinomed, VAS, Strabag, Agrana and Zumtobel.

BSN engine weekly Spitout: The **ATX TR** up 0,15% to 8.424,52 points this week. Year-to-date the ATX TR is now at **10,62%**. Up to now there were **115** days with a positive and **86** with a negative gain. From the year-high we are **3,24%** away, from the low **14,21%**. Statistically the best weekday so far 2024 is **Thursday** with 0,15%, the weakest is **Tuesday** with -0,12%.


These are the best-performers this week: **Porr** 8,69% in front of **RBI** 6,08% and **Addiko Bank** 5,21%. And the following stocks performed worst: **voestalpine** -6,18% in front of **Immofinanz** -4,24% and **Mayr-Melnhof** -4,1%.

Further highlights this week: **VIG** for 3 days in a row up (2,8% gain from 28,6 to 29,4), also **Erste Group** 3 days up (2,37% gain from 48,43 to 49,58), **OMV** 3 days up (2,03% gain from 38,42 to 39,2), **RBI** 3 days up (5,6% gain from 17,51 to 18,49), **SBO** 4 days down (2,13% loss from 30,55 to 29,9), **Palfinger** 3 days down (3,89% loss from 21,85 to 21).

Best-performers year-to-date as of now: **S Immo** 76% (last year: 0,16 percent) followed by **Addiko Bank** 51,31% (last year: 5,53 percent) and **Bawag** 44,85% (last year: -3,65 percent). And the worst-performing stocks year-to-date: **Pierer Mobility** -52,31% (Vorjahr: -26,59 percent), followed by **Mayr-Melnhof** -33,41% (Vorjahr: -16,27 percent) and **SBO** -32,35% (Vorjahr: -24,05 percent).

High above the MA200: **EuroTeleSites AG** 25,69%, **Bawag** 16,87% and **S Immo** 15,3%.

Down under the MA200: **Pierer Mobility** -37,02%, **Immofinanz** -27,82% and **Mayr-Melnhof** -23,51%.



wienerberger: wienerberger, a provider of innovative, ecological solutions for the entire building envelope, in the fields of new build and renovation, as well as infrastructure in water and energy management, announces two successful acquisitions in Northern Europe: a majority stake in Slatek OY, a key player in smart automation solutions for water utilities in Finland, and the complete takeover of Tekken AS, a leading supplier of pumping stations, prefabricated PE products and related services in Norway. These companies will add roughly € 10 million in revenue to wienerberger's business.

Wienerberger: weekly performance: -2.80%

14.76	8.69%	16.22%
Österreichische Post		
29.60	-0.17%	-9.48%
Polytec Group		
2.73	0.37%	-22.11%
RBI		
18.49	6.08%	-0.96%
RWT AG		
3.70	14.91%	-7.50%
Kontron		
16.98	4.75%	-21.10%
Semperit		
11.70	2.63%	-17.37%
S Immo		
22.00	-0.90%	76.00%
Sportradar Group		
11.00	2.80%	10.94%
Strabag		
37.85	0.80%	-8.57%
Telekom Austria		
8.59	1.30%	12.29%
UBM		
20.10	-0.99%	-4.74%
Uniqqa		
7.31	-0.54%	-2.01%
Varta AG		
5.05	255.63%	-75.66%
VAS AG		
7.50	-6.25%	-15.73%
Verbund		
74.00	0.34%	-11.96%
VIG		
29.40	1.03%	10.94%
Valneva		
2.51	-3.90%	-46.78%
Wienerberger		
27.80	-2.80%	-8.01%
Warimpex		
0.66	0.30%	-11.68%
Zumtobel		
5.50	0.36%	-12.42%

TUESDAY

08

Marinomed: Marinomed Biotech AG has published clinical data from the phase II dose-finding clinical trial evaluating the efficacy of Tacrosolv eye drops in patients with allergic rhinoconjunctivitis in the peer-reviewed "Clinical Ophthalmology" journal. The placebo-controlled allergen challenge trial assessed the efficacy and safety of two different doses of Tacrosolv. The results show that the higher dose of Tacrosolv eye drops (0.005% Tacrolimus) significantly reduced ocular symptoms of allergic conjunctivitis, and surprisingly, also the associated nasal allergy symptoms. Remarkably, these results were achieved with a dose that is 20-fold lower than that of the only Tacrolimus eye drop product currently on the market.

Marinomed Biotech: weekly performance: 0.21%

WEDNESDAY

09

VAS: Norbert Thurner has resigned from his position as a member of the board of VAS AG, one-stop provider of solid fuel-fired plants for generating heat and electricity. As the company announced, the board member with sole power of representation, Lukas Thurner, will continue to run the business alone.

Strabag: In close coordination with Austrian based construction group STRABAG SE, the Austrian core shareholders have filed a claim with a court of arbitration in Amsterdam concerning the rights of first refusal laid out in the 2007 syndicate agreement. The court must now clarify the following in particular: · the validity of the rights of first refusal beyond termination of the syndicate agreement from 2007 · the triggering of first refusal rights through change of control · the possibility to transfer shares under compliance with sanctions regimes "Our position since the start of the war has been clear and we have taken decisive steps to distance ourselves from the sanctioned shareholder. With the capital measure completed in March of this year, we succeeded in pushing the affected shareholdings below the important threshold of 25%. The fact that a STRABAG shareholder remains sanctioned, along with the uncertainties resulting from its transfer to Iliadis, nevertheless represent a persistent risk for our company. Rasperia's sale in Russia by Valtoura to Iliadis now gives us the opportunity to finally separate ourselves from the sanctioned shareholder. We are therefore pushing ahead with this process using every means at our disposal," says Klemens Haselsteiner, CEO of STRABAG SE.

Strabag: weekly performance: 0.80%

THURSDAY

10

Agrana: In the first half of the 2024|25 financial year, AGRANA, the fruit, starch and sugar company, registered a significant year-on-year decrease of 49.0% in operating profit (EBIT) to € 56.6 million. The Group's revenue eased by 5.0% to € 1,861.7 million (H1 prior year: € 1,959.5 million). The reduction in EBIT and revenue resulted from a decline in sales prices for sugar and lower margins on starch and saccharification products compared to the year before. The Fruit segment, on the other hand, delivered a very satisfactory performance, with EBIT significantly above that of the previous year. In the sugar market, the coming months will remain very challenging. Strong initial harvest forecasts in Europe, coupled

with
love
from
Vienna



Publisher: FC Chladek Drastil GmbH,
Czerninpl. 4, 1020 Wien · complete im-
print: boerse-social.com/impressum ·
editors: Christian Drastil ; Christine
Petzwinkler · bsngine:
Josef Chladek, Christian Drastil

subscription: boerse-social.com/21st

with substantially risen imports from Ukraine, have in the past months led to elevated supply, which in combination with flat demand has significantly driven down sugar prices. “The currently very adverse market situation will have a negative impact on the earnings of the AGRANA Group for the 2024|25 financial year. Although our diversified business model acts as a buffer against economic swings, we continue to work at full speed on our Next Level strategy in order to reduce our exposure to market volatility and increase our baseline profitability. We have already initiated measures to this end, including a comprehensive cost reduction programme both at the holding company and segment level. In the volatile commodity markets where we operate, cost leadership is crucial. On this front we intend to fully leverage our existing potential,” says AGRANA CEO Stephan Büttner.

Agrana: weekly performance: -0.46%

FRIDAY

11

Marinomed: Marinomed Biotech AG announced that, after a thorough review of existing offers, the Management Board today decided to enter contract negotiations for the sale of the Carragelose portfolio in the form of an asset deal. The Company selected the potential buyer based on a combination of favorable purchase price, transaction security and strategic fit, thereby providing a long-term perspective for the Company. The actual implementation of the transaction depends on the outcome of the specific negotiations, the conclusion of the respective transaction documents, the approval of the Supervisory Board and the General Shareholder Assembly, as well as the continuation of the Company after the restructuring process. In addition, due to the ongoing restructuring process, approvals from the insolvency administrator and the insolvency court are necessary. These approvals have not yet been obtained.

Zumtobel: The Supervisory Board of the Zumtobel Group has extended the contract of Chief Executive Officer Alfred Felder (61), which is due to expire as of 31 July 2025, until 30 September 2027. With the repeated renewal of his contract, the Supervisory Board focuses on continuity in the Management Board of the Zumtobel Group and recognises the achievements of Alfred Felder, who has navigated the company through difficult times. On 1 February 2018, Alfred Felder took over the role of Acting President of the Management Board; on 8 June 2018, he was appointed Chief Executive Officer (CEO).

Zumtobel: weekly performance: 0.36%

THE NEXT 21st AUSTRIA WEEKLY WILL BE
ISSUED NEXT SATURDAY
HEAR OUR ENGLISH SPOKEN STOCK MARKET
PODCAST WITH ALLISON AND CHRIS EVERY
SUNDAY ON CHRISTIAN-DRASTIL.COM/
PODCAST

